Statement on FDA's Approval of XENAZINE(R) for the Treatment of Chorea Associated With Huntington's Disease

Saturday, August 16, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Aug. 15 The Hereditary Disease Foundation (HDF)is extremely pleased the U.S. Food and Drug Administration has approvedXenazine, or tetrabenazine, for the treatment of chorea associated withHuntington's disease.

"Chorea is a major cause of disability and death in patients withHuntington's disease. Chorea is not just a mere inconvenience; it can preventHuntington's disease patients from walking, talking, working, watchingtelevision and almost every aspect of one's life. We are ecstatic that,through the approval of Xenazine, patients and families will have the optionto take the only drug developed specifically for treating the movements ofHuntington's disease," said Nancy Wexler, Ph.D., Higgins Professor ofNeuropsychology in the departments of neurology and psychiatry at ColumbiaUniversity and president of the Hereditary Disease Foundation.

"While we are still hopeful we can some day find a cure, the approval ofXenazine is a breakthrough for the Huntington's disease community," said Dr.Wexler.

The approval of Xenazine marks the first and only FDA-approved treatmentfor any symptom of Huntington's disease.

SOURCE Hereditary Disease Foundation


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook